

Antonio Craxi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4540919/antonio-craxi-publications-by-year.pdf>

Version: 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

361
papers

24,968
citations

69
h-index

151
g-index

388
ext. papers

28,463
ext. citations

6.3
avg, IF

6.39
L-index

#	Paper	IF	Citations
361	A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.. <i>BMC Infectious Diseases</i> , 2022 , 22, 58	4	1
360	Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022 ,	4.5	1
359	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , 2022 , 11, 75-84	9.1	4
358	Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy.. <i>BMC Infectious Diseases</i> , 2022 , 22, 3	4	1
357	Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Viruses</i> , 2022 , 14, 986	6.2	4
356	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021 , 53, 1301-1307	3.3	2
355	Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. <i>Epidemics</i> , 2021 , 34, 100442	5.1	9
354	Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8-Weeks' Glecaprevir/Pibrentasvir Therapy. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 763-774	6.2	1
353	Reply to: "Hepatic benefits of HCV cure: Don't forget coagulation!". <i>Journal of Hepatology</i> , 2021 , 74, 969	13.4	
352	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1190-1199	3.4	3
351	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2389-2396	4	3
350	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2345-2353	4.5	17
349	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021 , 74, 31-36	13.4	80
348	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
347	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
346	SARS-CoV-2 infection in patients with a normal or abnormal liver. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 4-11	3.4	13
345	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. <i>Liver International</i> , 2021 , 41, 649-655	7.9	7

344	Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1248-1255	0.7	2
343	Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. <i>Advances in Therapy</i> , 2021 , 38, 1397-1403	4.1	0
342	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. <i>Liver International</i> , 2021 , 41, 934-948	7.9	6
341	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , 2021 ,	7.9	2
340	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1979-1981	6.9	4
339	EASL Recognition Awardee 2020: Prof. Giovanna Fattovich. <i>Journal of Hepatology</i> , 2020 , 73, 484-486	13.4	
338	Extrahepatic Manifestations of Chronic Viral C Hepatitis. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 347-360	4.4	8
337	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020 , 40, 1545-1555	7.9	19
336	Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct-acting antivirals? 2020 , 231-237		
335	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 13,	6.6	3
334	Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?. <i>Annali Dell'istituto Superiore Di Sanita</i> , 2020 , 56, 325-329	1.6	5
333	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020 , 15, e0243590	3.7	0
332	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020 , 296, 40-47	3.1	36
331	Will the COVID-19 pandemic affect HCV disease burden?. <i>Digestive and Liver Disease</i> , 2020 , 52, 947-949	3.3	10
330	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020 , 40, 2820-2827	7.9	9
329	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2408-2418	6.7	28
328	Hepatic benefits of HCV cure. <i>Journal of Hepatology</i> , 2020 , 73, 1548-1556	13.4	22
327	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 2103-2110	4.5	3

326	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020 , 12,	6.6	10
325	Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. <i>Liver International</i> , 2020 , 40, 2590-2601	7.9	5
324	SARS-CoV-2 Viral Load, IFN Polymorphisms and the Course of COVID-19: An Observational Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	21
323	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020 , 71, 1213-1227	12.7	104
322	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , 2019 , 9, 585	4.9	6
321	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , 2019 , 39, 1742-1754	7.9	37
320	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , 2019 , 51, 915-921	3.3	8
319	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 1325-1334	7.9	23
318	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42
317	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019 , 71, 265-273	13.4	80
316	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019 , 8,	7.9	9
315	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-128	5.3	5
314	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 118-125	3.4	11
313	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018 , 155, 411-421.e4	13.3	201
312	Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. <i>Gut</i> , 2018 , 67, 403-404	4.4	
311	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018 , 67, 1754-1767	11.2	376
310	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , 2018 , 38, 2108-2116	7.9	13
309	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 740-749	6.1	12

308	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018 , 38, 2190-2198	7.9	23
307	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
306	Current and future challenges in HCV: insights from an Italian experts panel. <i>Infection</i> , 2018 , 46, 147-163	5.8	3
305	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , 2018 , 32, e13165	3.8	9
304	Expert opinion on managing chronic HCV in patients with cardiovascular disease. <i>Antiviral Therapy</i> , 2018 , 23, 35-46	1.6	5
303	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
302	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 1157-1166	7.9	53
301	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
300	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 65-71	13.4	63
299	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017 , 37, 1389-1396	7.9	26
298	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
297	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017 , 37, 1526-1534	7.9	29
296	Between reality and the guidelines: A survey on perception, diagnosis and management of hepatic encephalopathy in 201 Italian specialist centres. <i>Digestive and Liver Disease</i> , 2017 , 49, 828-830	3.3	3
295	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2660-2669	5.6	30
294	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1604-1611.e1	6.9	83
293	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 325-336	18.8	153
292	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. <i>PLoS ONE</i> , 2017 , 12, e0186136	3.7	38
291	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29

290	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017 , 66, 1814-1825	11.2	18
289	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
288	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 688-695	6.1	104
287	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 160-168	6.1	58
286	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. <i>Digestive and Liver Disease</i> , 2016 , 48, 1314-1317	3.3	4
285	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
284	Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. <i>Journal of Hepatology</i> , 2016 , 65, 861-862	13.4	63
283	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016 , 150, 145-155.e4; quiz e15-6	13.3	156
282	Reply. <i>Hepatology</i> , 2016 , 64, 701	11.2	
281	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016 , 36, 198-204	7.9	12
280	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , 2016 , 151, 130-139.e2	13.3	107
279	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015 , 61, 506-14	11.2	311
278	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 193-200	5.6	21
277	The UCP2 -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015 , 35, 1574-80	7.9	35
276	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 477-86	6.1	12
275	Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. <i>Journal of Medical Economics</i> , 2015 , 18, 678-90	2.4	18
274	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 939-48	6.1	16
273	Response to Dr. Sertoglu and colleagues. <i>Liver International</i> , 2015 , 35, 285-6	7.9	

272	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1037-46	4.1	42
271	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015 , 11, 449-65	3.6	17
270	Extrahepatic morbidity and mortality of chronic hepatitis C. <i>Gastroenterology</i> , 2015 , 149, 1345-60	13.3	230
269	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , 2015 , 10, 977-88	2.9	2
268	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015 , 62, 928-33	13.4	115
267	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015 , 35, 1566-73	7.9	94
266	Clinical course and management of acute and chronic viral hepatitis during pregnancy. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 515-23	3.4	12
265	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
264	HCV: the best cure possible or the best possible cure?. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 627-9	3.4	5
263	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015 , 62, 1101-10	11.2	131
262	Impact of HBV genotypes A and D genetic variability on infection evolution. <i>Infection, Genetics and Evolution</i> , 2015 , 33, 281-7	4.5	4
261	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015 , 63, 705-12	3.4	227
260	Epicardial fat in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015 , 62, 1215	13.4	3
259	Current and future HCV therapy: do we still need other anti-HCV drugs?. <i>Liver International</i> , 2015 , 35 Suppl 1, 4-10	7.9	23
258	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. <i>Hepatology</i> , 2015 , 62, 784-91	11.2	83
257	Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal. <i>Internal and Emergency Medicine</i> , 2014 , 9, 601-2	3.7	
256	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014 , 59, 1692-705	11.2	64
255	Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014 , 60, 1075-89	13.4	56

254	HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?. <i>Journal of Hepatology</i> , 2014 , 61, 1430-3	13.4	11
253	A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding. <i>Digestive and Liver Disease</i> , 2014 , 46, 783-7	3.3	18
252	Clinical implications of the hyperdynamic syndrome in cirrhosis. <i>European Journal of Internal Medicine</i> , 2014 , 25, 795-802	3.9	33
251	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 818-25	3.3	8
250	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 936-42	3.3	14
249	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. <i>Digestive and Liver Disease</i> , 2014 , 46, 1116-20	3.3	28
248	Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?". <i>Journal of Hepatology</i> , 2014 , 61, 173-5	13.4	
247	HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2014 , 23, 80-5	4.5	2
246	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014 , 384, 403-13	4.0	394
245	White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014 , 46, 579-89	3.3	30
244	Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey. <i>Clinical Medicine Insights Gastroenterology</i> , 2014 , 7, 25-31		22
243	Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 303-10	1.7	16
242	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , 2014 , 63, 369-75	19.2	60
241	Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?. <i>Liver International</i> , 2014 , 34 Suppl 1, 85-90	7.9	47
240	Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 388-95	2.2	2
239	Management of infections in cirrhotic patients: report of a consensus conference. <i>Digestive and Liver Disease</i> , 2014 , 46, 204-12	3.3	36
238	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". <i>Journal of Hepatology</i> , 2014 , 60, 677-8	13.4	1
237	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 878-884.e1	6.9	10

236	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, 523-9	13.4	57
235	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014 , 60, 16-21	13.4	23
234	CT enterography as a powerful tool for the evaluation of inflammatory activity in Crohn's disease: relationship of CT findings with CDAI and acute-phase reactants. <i>Radiologia Medica</i> , 2014 , 119, 658-66	6.5	27
233	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e87523	3.7	83
232	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , 2014 , 9, e110857	3.7	13
231	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013 , 59, 1169-76	13.4	28
230	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , 2013 , 58, 792-800	13.4	88
229	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 867-74	3.4	67
228	Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. <i>Gastroenterology</i> , 2013 , 145, 1035-1044.e5	13.3	42
227	Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1355-61	3.5	11
226	Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 311-7.e1	6.9	27
225	Reply: To PMID 22135089. <i>Hepatology</i> , 2013 , 57, 422	11.2	
224	Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". <i>Journal of Hepatology</i> , 2013 , 58, 403-4	13.4	3
223	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013 , 45, 712-23	3.3	128
222	Herbal hepatotoxicity: a hidden epidemic. <i>Internal and Emergency Medicine</i> , 2013 , 8, 13-22	3.7	43
221	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 113-21	3.4	16
220	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 174-82	3.4	10
219	How to optimize HCV therapy in genotype 1 patients: predictors of response. <i>Liver International</i> , 2013 , 33 Suppl 1, 23-9	7.9	19

218	Osteodystrophy in chronic liver diseases. <i>Internal and Emergency Medicine</i> , 2013 , 8, 377-88	3.7	11
217	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 658-66	13.4	34
216	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 486-93	3.4	42
215	Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. <i>Journal of Clinical Gastroenterology</i> , 2013 , 47, 786-93	3	1
214	Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 790-800	3.4	10
213	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 57, 1046-54	11.2	78
212	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013 , 5, 685-91	3.4	18
211	NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. <i>PLoS ONE</i> , 2013 , 8, e68364	3.7	20
210	Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. <i>PLoS ONE</i> , 2013 , 8, e70016	3.7	20
209	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2013 , 8, e74089	3.7	47
208	HCV genotype 5: an orphan virus. <i>Antiviral Therapy</i> , 2013 , 18, 263-9	1.6	3
207	Immunological alterations in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8916-23	5.6	22
206	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 465-72	3.4	8
205	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , 2012 , 97, 679-86	6.6	41
204	Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 766-74	3.4	14
203	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. <i>Liver International</i> , 2012 , 32, 1443-50	7.9	15
202	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012 , 56, 1356-62	13.4	72
201	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012 , 57, 821-9	13.4	589

200	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. <i>Digestive and Liver Disease</i> , 2012 , 44, 245-50	3.3	9
199	Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2012 , 44, 674-80	3.3	15
198	Phylogenetic analysis of isolates from new cases of HBV infection in Southern Italy. <i>Infection, Genetics and Evolution</i> , 2012 , 12, 1591-6	4.5	6
197	Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. <i>Internal and Emergency Medicine</i> , 2012 , 7, 337-42	3.7	10
196	Serum γ -glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. <i>PLoS ONE</i> , 2012 , 7, e51165	3.7	24
195	Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. <i>Hepatology</i> , 2012 , 55, 1317-23	11.2	105
194	Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?. <i>Hepatology</i> , 2012 , 55, 1309; author reply 1309-10	11.2	1
193	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012 , 56, 850-60	11.2	91
192	Fluoroquinolone-induced liver injury: three new cases and a review of the literature. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 525-32	2.8	17
191	Should cirrhosis change our attitude towards treating non-hepatic cancer?. <i>Liver International</i> , 2012 , 32, 21-7	7.9	17
190	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , 2012 , 32 Suppl 1, 2-8	7.9	83
189	Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response. <i>Journal of Viral Hepatitis</i> , 2012 , 19, e120-5	3.4	4
188	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 238-47	6.1	74
187	Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 490-490	6.1	0
186	Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. <i>Antiviral Therapy</i> , 2012 , 17, 111-8	1.6	8
185	Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 504-8	3	25
184	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , 2012 , 17, 823-31	1.6	28
183	Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2012 , 4, 256-61	3.4	59

182	Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension. <i>Digestive and Liver Disease</i> , 2011 , 43, 48-53	3.3	16
181	Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011 , 43, 259-65	3.3	25
180	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011 , 43, 404-10	3.3	24
179	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2112-20	0.7	148
178	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC program. <i>Journal of Hepatology</i> , 2011 , 54, 227-35	13.4	16
177	Genetic predisposition to thrombophilia in inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, e25-9	3	4
176	Hepatitis Due to Non-AE Viruses 2011 , 427-437		
175	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1350-60	6.1	104
174	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 196-204	6.1	46
173	Is liver stiffness measurement unreliable in obese patients? authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 255-256	6.1	
172	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 757-66	6.1	95
171	Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1043-1044	6.1	
170	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. <i>Liver International</i> , 2011 , 31 Suppl 1, 36-44	7.9	8
169	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011 , 31, 507-15	7.9	58
168	Halitosis: could it be more than mere bad breath?. <i>Internal and Emergency Medicine</i> , 2011 , 6, 315-9	3.7	19
167	Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C. <i>Hepatology</i> , 2011 , 54, 373-4; author reply 374	11.2	1
166	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , 2011 , 60, 1023	19.2	9
165	The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. <i>Liver International</i> , 2010 , 30, 342-55	7.9	128

164	Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. <i>British Journal of Haematology</i> , 2010 , 148, 476-9	4.5	45
163	Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. <i>Current Pharmaceutical Design</i> , 2010 , 16, 741-52	3.3	52
162	Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. <i>Digestive and Liver Disease</i> , 2010 , 42, 143-8	3.3	23
161	Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. <i>Digestive and Liver Disease</i> , 2010 , 42, 585-92	3.3	24
160	Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. <i>Digestive and Liver Disease</i> , 2010 , 42 Suppl 3, S287-92	3.3	4
159	PEG IFN alfa-2a vs. alfa-2b: and the winner is ...?. <i>Journal of Hepatology</i> , 2010 , 52, 133-5	13.4	6
158	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010 , 116, 2875-83	2.2	65
157	Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 469-74	3.4	23
156	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010 , 51, 1274-83	11.2	292
155	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2010 , 51, 1158-67	11.2	318
154	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. <i>Hepatology</i> , 2010 , 51, 1858-1858	11.2	
153	Reply:. <i>Hepatology</i> , 2010 , 51, 2230-2230	11.2	
152	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010 , 52, 1543-52	11.2	76
151	Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3625-34		43
150	Hepatitis B: Prognosis and Treatment 2010 , 448-464		
149	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2132-8	5.6	27
148	Multimodal approaches to the treatment of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009 , 6, 159-69	24.2	59
147	Hepatocellular cancer: optimal strategies for screening and surveillance. <i>Digestive Diseases</i> , 2009 , 27, 142-7	3.2	28

146	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009 , 49, 195-203	11.2	56
145	Reply:. <i>Hepatology</i> , 2009 , 49, 1394-1395	11.2	
144	HCV genotypes in Sicily: is there any evidence of a shift?. <i>Journal of Medical Virology</i> , 2009 , 81, 1040-6	19.7	16
143	Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 955-65		179
142	Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 227-35	6.1	17
141	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 603-13	6.1	20
140	Serum BLYS/BAFF predicts the outcome of acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 397-405	3.4	15
139	Implication of normal liver enzymes in liver disease. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 529-36	3.4	34
138	Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review. <i>Liver International</i> , 2009 , 29 Suppl 1, 31-8	7.9	7
137	Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. <i>Liver International</i> , 2009 , 29, 1171-7	7.9	19
136	Metastatic hepatocellular carcinoma of the parotid region without lung metastasis: a case report. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2009 , 38, 696-8	2.9	9
135	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. <i>Journal of Hepatology</i> , 2009 , 51, 675-81	13.4	20
134	Non-alcoholic fatty liver disease pathogenesis: the present and the future. <i>Digestive and Liver Disease</i> , 2009 , 41, 615-25	3.3	190
133	Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. <i>Gastroenterology</i> , 2009 , 136, 1618-28.e2	13.3	197
132	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 281-91	5.5	7
131	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 293-308	5.5	54
130	Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?. <i>Antiviral Therapy</i> , 2009 , 14, 1045-9	1.6	
129	Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. <i>Journal of Oral Pathology and Medicine</i> , 2009 , 38, 34-41	3.3	4

128	Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2628-31	5.6	69
127	Needle track seeding following percutaneous procedures for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2009 , 1, 62-6	3.4	19
126	Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2009 , 14, 649-654	1.6	39
125	Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 62-75	6.1	64
124	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 523-30	3.4	15
123	Extrahepatic manifestations of hepatitis C virus infection. <i>Clinics in Liver Disease</i> , 2008 , 12, 611-36, ix	4.6	52
122	Coeliac disease: oral ulcer prevalence, assessment of risk and association with gluten-free diet in children. <i>Digestive and Liver Disease</i> , 2008 , 40, 104-7	3.3	33
121	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. <i>Digestive and Liver Disease</i> , 2008 , 40, 684-9	3.3	25
120	Hepatitis C virus (HCV) infection: a systemic disease. <i>Molecular Aspects of Medicine</i> , 2008 , 29, 85-95	16.7	67
119	Inguinal hernioplasty improves the quality of life in patients with cirrhosis. <i>American Journal of Surgery</i> , 2008 , 196, 373-8	2.7	29
118	Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1136-44	0.7	149
117	Liver disease in chelated transfusion-dependent thalasseemics: the role of iron overload and chronic hepatitis C. <i>Haematologica</i> , 2008 , 93, 1243-6	6.6	41
116	Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 66-70	3.4	3
115	Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: the Camporeale model. <i>Journal of Medical Virology</i> , 2008 , 80, 1723-31	19.7	20
114	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008 , 48, 28-37	11.2	49
113	Introduction. Necroinflammation and the course of chronic hepatitis. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 3, S369-71	3.3	
112	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1181-91	6.1	59
111	Oral mucosa of coeliac disease patients produces antiendomysial and antitransglutaminase antibodies: the diagnostic usefulness of an in vitro culture system. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1471-7	6.1	11

110	Oral pathology in untreated coeliac [corrected] disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1529-36	6.1	33
109	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. <i>Journal of Hepatology</i> , 2007 , 47, 484-91	13.4	84
108	Adefovir for lamivudine resistant HBV: more than meets the eye. <i>Journal of Hepatology</i> , 2007 , 47, 618-9; author reply 619-20	13.4	2
107	Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?. <i>Journal of Hepatology</i> , 2007 , 47, 580-7	13.4	29
106	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 64-71	11.2	147
105	Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. <i>Journal of Medical Virology</i> , 2006 , 78, 1304-11	19.7	8
104	Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. <i>Journal of Hepatology</i> , 2006 , 44, 4-7	13.4	6
103	Treatment options in HBV. <i>Journal of Hepatology</i> , 2006 , 44, S77-83	13.4	23
102	Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. <i>Journal of Hepatology</i> , 2006 , 45, 271-9	13.4	77
101	From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). <i>Journal of Hepatology</i> , 2006 , 44, 1186-95	13.4	8
100	Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 351-4	3.4	11
99	Prevention of hepatocellular carcinoma. <i>Clinics in Liver Disease</i> , 2005 , 9, 329-46, viii	4.6	46
98	Treatment of hepatitis C: critical appraisal of the evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 399-408	4	17
97	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005 , 42, 535-40	13.4	89
96	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. <i>Journal of Hepatology</i> , 2005 , 43, 425-33	13.4	425
95	Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. <i>Digestive and Liver Disease</i> , 2005 , 37, 446-50	3.3	2
94	Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. <i>Digestive and Liver Disease</i> , 2005 , 37, 850-60	3.3	28
93	Response to letter from Professor Peter Ferenci. <i>Digestive and Liver Disease</i> , 2005 , 37, 808-809	3.3	

92	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. <i>Digestive and Liver Disease</i> , 2005 , 37, 882-5	3.3	19
91	Hepatitis B virus reactivation and alemtuzumab therapy. <i>European Journal of Haematology</i> , 2005 , 74, 254-8	3.8	97
90	Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2472-7	0.7	48
89	Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 257-62	3.4	41
88	HCV infection and oral lichen planus: a weak association when HCV is endemic. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 465-70	3.4	20
87	Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. <i>Hepatology</i> , 2004 , 39, 333-42	11.2	169
86	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C. <i>Pharmacoeconomics</i> , 2004 , 22, 257-65	4.4	55
85	Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. <i>Gut</i> , 2004 , 53, 925-30	19.2	401
84	Early virologic response with pegylated interferons. <i>Digestive and Liver Disease</i> , 2004 , 36 Suppl 3, S340-33.3		7
83	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. <i>Gastroenterology</i> , 2004 , 126, 102-10	13.3	327
82	Characteristics of liver cirrhosis in Italy: results from a multicenter national study. <i>Digestive and Liver Disease</i> , 2004 , 36, 56-60	3.3	25
81	The aetiology of chronic hepatitis in Italy: results from a multicentre national study. <i>Digestive and Liver Disease</i> , 2004 , 36, 829-33	3.3	20
80	Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1490-6	0.7	49
79	Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 364-70	4.5	15
78	HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. <i>Journal of Hepatology</i> , 2004 , 40, 831-6	13.4	38
77	Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004 , 41, 474-81	13.4	83
76	The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. <i>Current Pharmaceutical Design</i> , 2004 , 10, 2123-30	3.3	20
75	Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , 2004 , 40, 883-91	11.2	199

74	Clinical trial results of peginterferons in combination with ribavirin. <i>Seminars in Liver Disease</i> , 2003 , 23 Suppl 1, 35-46	7.3	18
73	Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. <i>Pathology Research and Practice</i> , 2003 , 199, 65-70	3.4	16
72	Pegylated interferons for chronic hepatitis B. <i>Antiviral Research</i> , 2003 , 60, 87-9	10.8	40
71	A patient with acute hepatitis C and possible IFN toxicity. <i>Digestive and Liver Disease</i> , 2003 , 35, 372-3	3.3	0
70	Parvovirus B19 and "cryptogenic" chronic hepatitis. <i>Journal of Hepatology</i> , 2003 , 38, 375-6	13.4	13
69	IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. <i>Human Immunology</i> , 2003 , 64, 674-80	2.3	80
68	When and how to treat acute hepatitis C?. <i>Journal of Hepatology</i> , 2003 , 39, 1056-62	13.4	68
67	Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. <i>Journal of Medical Virology</i> , 2002 , 67, 339-44	19.7	76
66	Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. <i>Journal of Viral Hepatitis</i> , 2002 , 9, 354-9	3.4	12
65	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002 , 51, 864-9	19.2	19
64	Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?. <i>Digestive and Liver Disease</i> , 2002 , 34, 53-8	3.3	5
63	Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2002 , 34, 656-9	3.3	7
62	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , 2002 , 347, 975-82	59.2	5551
61	High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 953-8	6.1	5
60	Multiple voltage-gradient gel electrophoresis system. <i>Electrophoresis</i> , 2001 , 22, 29-32	3.6	9
59	Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. <i>Hepatology</i> , 2001 , 33, 333-8	11.2	182
58	Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. <i>Gut</i> , 2001 , 48, 843-8	19.2	69
57	Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. <i>Digestive and Liver Disease</i> , 2001 , 33, 795-802	3.3	17

56	Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 1645-52	6.1	39
55	Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. <i>Journal of Hepatology</i> , 2000 , 33, 456-62	13.4	40
54	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 1013-9	4	11
53	The long-term course of chronic hepatitis B. <i>Hepatology</i> , 1999 , 30, 257-64	11.2	170
52	Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). <i>Hepatology</i> , 1999 , 30, 238-43	11.2	107
51	Surgery in patients with liver disease. <i>Hepatology</i> , 1999 , 30, 820-1	11.2	3
50	Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). <i>Hepatology</i> , 1999 , 30, 801-7	11.2	24
49	Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. <i>Alimentary Pharmacology and Therapeutics</i> , 1998 , 12, 1091-9	6.1	19
48	Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases. <i>Clinical and Experimental Immunology</i> , 1998 , 114, 102-5	6.2	6
47	Characteristics of hepatocellular carcinoma in Italy. <i>Journal of Hepatology</i> , 1998 , 29, 944-52	13.4	134
46	Long-term course of interferon-treated chronic hepatitis C. <i>Journal of Hepatology</i> , 1998 , 28, 531-7	13.4	71
45	Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. <i>New England Journal of Medicine</i> , 1998 , 339, 1493-9	59.2	1103
44	Decrease in HDV endemicity in Italy. <i>Journal of Hepatology</i> , 1997 , 26, 20-4	13.4	72
43	A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , 1997 , 51, 17-24	19.7	19
42	Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. <i>Journal of Hepatology</i> , 1996 , 24, 517-24	13.4	66
41	Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. <i>Journal of Hepatology</i> , 1996 , 24, 539-46	13.4	20
40	HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). <i>Journal of Hepatology</i> , 1996 , 25, 583-90	13.4	32
39	Interferon as treatment for acute hepatitis C. A meta-analysis. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 1248-55	4	63

38	Epidemiology of viral hepatitis and HCC in Italy. <i>International Hepatology Communications</i> , 1996 , 5, 10-13		
37	Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 33-40	4	31
36	Host and viral features in chronic HCV infection: relevance to interferon responsiveness. <i>Research in Virology</i> , 1995 , 146, 273-8		7
35	A multicenter randomized controlled trial of recombinant interferon- α 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994 , 19, 19-22	11.2	93
34	The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). <i>Journal of Hepatology</i> , 1994 , 21, 646-55	13.4	73
33	Third-generation hepatitis C virus tests in asymptomatic anti-HCV-positive blood donors. <i>Journal of Hepatology</i> , 1994 , 21, 730-4	13.4	16
32	A multicenter randomized controlled trial of recombinant interferon- α 2b in patients with acute transfusion-associated hepatitis C 1994 , 19, 19		4
31	Long-term evolution of chronic delta hepatitis in children. <i>Journal of Pediatrics</i> , 1993 , 122, 736-8	3.6	13
30	Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. <i>Journal of Hepatology</i> , 1993 , 18, 154-62	13.4	76
29	The natural history of chronic HDV infection. <i>Progress in Clinical and Biological Research</i> , 1993 , 382, 301-10		2
28	The epidemiology of hepatitis delta infection in Italy. Promoting Group. <i>Journal of Hepatology</i> , 1992 , 15, 211-5	13.4	48
27	Anti-HCV, anti-GOR, and autoimmunity. <i>Lancet, The</i> , 1992 , 339, 871-872	40	18
26	Hepatitis C virus and Sjögren's syndrome. <i>Lancet, The</i> , 1992 , 339, 989-90	40	30
25	Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. <i>Journal of Medical Virology</i> , 1992 , 38, 200-6	19.7	34
24	Baseline sero-epidemiology of hepatitis B virus infection in children and teenagers in Italy. A survey before mass hepatitis B vaccination. <i>Journal of Infection</i> , 1991 , 22, 191-9	18.9	46
23	Second generation tests in diagnosis of chronic hepatitis C. <i>Lancet, The</i> , 1991 , 337, 1354	40	22
22	A performance evaluation of the expert system 'Jaundice' in comparison with that of three hepatologists. <i>Journal of Hepatology</i> , 1991 , 13, 279-85	13.4	5
21	Is autoimmune chronic active hepatitis a HCV-related disease?. <i>Journal of Hepatology</i> , 1991 , 13, 56-60	13.4	59

20	Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. <i>Journal of Hepatology</i> , 1991 , 12, 64-9	13.4	25
19	Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. <i>Journal of Hepatology</i> , 1991 , 13, 192-9	13.4	264
18	Hepatitis C virus replication in chronic liver disease. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S40-1	13.4	
17	Hepatitis C virus replication in 'autoimmune' chronic hepatitis. <i>Journal of Hepatology</i> , 1991 , 13, 364-7	13.4	55
16	Treatment with interferon alfa-2b of chronic HDV hepatitis in children. <i>Journal of Hepatology</i> , 1990 , 11, S175	13.4	6
15	Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine. <i>European Journal of Epidemiology</i> , 1989 , 5, 65-9	12.1	3
14	Interleukin-2, interleukin-2 receptor and gamma-interferon synthesis by peripheral blood mononuclear cells in chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , 1989 , 8, 358-66	13.4	13
13	Detection of hepatitis delta virus RNA in chronic liver disease. <i>Journal of Hepatology</i> , 1989 , 9, 23-8	13.4	15
12	IgM anti-HBc in acute and chronic hepatitis B virus (HBV) infection: diagnostic value and correlation with viral replication and disease activity. <i>Bollettino Dell'istituto Sieroterapico Milanese</i> , 1988 , 67, 275-82		1
11	Autoimmunity in chronic liver disease caused by hepatitis delta virus. <i>Journal of Clinical Pathology</i> , 1986 , 39, 897-9	3.9	24
10	A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis. <i>Hepatology</i> , 1985 , 5, 7-9	11.2	19
9	Polyalbumin receptors, hepatitis B surface antigen (HBsAg), and HBsAg/IgM complexes in HBsAg positive patients with and without delta superinfection. <i>Journal of Medical Virology</i> , 1985 , 15, 383-8	19.7	7
8	Familiar clustering and spreading of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 1985 , 1, 221-6	13.4	37
7	Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. <i>Lancet, The</i> , 1985 , 2, 356-8	4.0	57
6	Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. <i>Hepatology</i> , 1983 , 3, 545-9	11.2	134
5	Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. <i>Digestive Diseases and Sciences</i> , 1983 , 28, 39-43	4	159
4	Severe rifampicin-associated liver failure in patients with compensated cirrhosis. <i>Lancet, The</i> , 1978 , 1, 774	4.0	6
3	PRIMARY BILIARY CIRRHOSIS AND CHOLANGIOLITHIASIS. <i>Lancet, The</i> , 1978 , 311, 713-714	4.0	5

2 Genotype 1 Relapsers and Non-Responders 84-89

1 Hepatitis B- a Therapeutic Vaccine: Hope or Hype? 230-235